Search

Showing total 1,886 results

Search Constraints

Start Over You searched for: Topic buprenorphine Remove constraint Topic: buprenorphine Publication Year Range Last 50 years Remove constraint Publication Year Range: Last 50 years Language english Remove constraint Language: english
1,886 results

Search Results

1. Minimally invasive detection of buprenorphine using a carbon-coated 3D-printed microneedle array.

2. Cognitive processing therapy (CPT) versus individual drug counseling (IDC) for PTSD for veterans with opioid use disorder maintained on buprenorphine.

3. Pregnancy Rates Among Women Treated with Medication for Opioid Use Disorder.

4. What the X? Understanding changes in buprenorphine prescribing regulation.

5. (RE-)AIMing for Rapid Uptake: Pilot Evaluation of a Modified Hub and Spoke Model of Medication for Opioid Use Disorder.

6. ASAM elaborates on its buprenorphine dosing paper

7. Analgesic Effect of Buprenorphine for Chronic Noncancer Pain: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

8. Exploring patient experience and satisfaction with depot buprenorphine formulations: A mixed-methods study.

9. Evaluation of the gap in delivery of opioid agonist therapy among individuals with opioid-related health problems: a population-based retrospective cohort study.

10. Comparative Safety Analysis of Opioid Agonist Treatment in Pregnant Women with Opioid Use Disorder: A Population-Based Study.

11. Converting adults with sickle cell disease from full agonist opioids to buprenorphine: A reliable method with safety and early evidence of reduced acute care utilization.

12. Opioid Use Disorder Treatment Initiation and Continuation: a Qualitative Study of Patients Who Received Addiction Consultation and Hospital-Based Providers.

13. Nudging Emergency Department-Initiated Addiction Treatment.

14. Effects of opioid rotation to buprenorphine/naloxone on pain, pain thresholds, pain tolerance, and quality of life in patients with chronic pain and opioid use disorder.

15. Emergency Department-initiated Buprenorphine and Referral to Follow-up Addiction Care: A Program Description.

16. The Geographic Impact of Buprenorphine Expansion to Nurse Practitioner Prescribers in Oregon.

17. Precipitated Withdrawal, Delirium, and Cerebellar Stroke: The Pharmacology of Buprenorphine Induction in Non-pharmaceutical Fentanyl and the Neuropsychiatric Manifestations of Cerebellar Stroke.

18. Behavioral counseling and abstinence-contingent take-home buprenorphine in general practitioners' offices in Malaysia: a randomized, open-label clinical trial.

19. Quantitative paper spray mass spectrometry analysis of drugs of abuse.

20. DEA Disconnect Leads to Buprenorphine Bottlenecks.

21. Provider Continuity in the Prescribing of Buprenorphine/Naloxone Within Medicare Part D.

22. Jail inmates now getting drug-soaked paper through mail, jails moving to stop it

23. Monitoring Prenatal Exposure to Buprenorphine and Methadone.

24. Assessment of Subjective Sleep Problems in Men With Opioid Dependence Maintained on Buprenorphine.

27. Reported analgesic and anaesthetic administration to non‐human primates undergoing experimental surgical procedure: 2010‐2015.

28. ASAM elaborates on its buprenorphine dosing paper.

29. Successful administration of extended-release buprenorphine in the emergency department.

30. Buprenorphine treatment and clinical outcomes under the opioid use disorder cascade of care.

31. Utilization of long-acting injectable monthly depot buprenorphine for opioid use disorder (OUD) in Kentucky, before and after COVID-19 related buprenorphine access policy changes.

32. Study protocol for the Treating Opioid Patients' Pain and Sadness (TOPPS) study - A randomized control trial to lower depression and chronic pain interference, and increase care retention among persons receiving buprenorphine.

33. Perceptions around medications for opioid use disorder among a diverse sample of U.S. adults.

34. Composition of buprenorphine prescribing networks in Medicaid and association with quality of care.

35. Buprenorphine for Cancer Pain: Results from a Systematic Review.

36. An explainable machine learning framework for predicting the risk of buprenorphine treatment discontinuation for opioid use disorder among commercially insured individuals.

37. Mediating effect of craving on the impact of buprenorphine/naloxone and methadone treatment on opioid use: Results from a randomized controlled trial.

38. OPRM1 rs2075572 has potential to affect plasma buprenorphine level in opioid users, but not OPRM1 rs562859.

39. Feasibility of Web-Based Single-Session Empowered Relief in Patients With Chronic Pain Taking Methadone or Buprenorphine: Protocol for a Single-Arm Trial.

40. Extended-release versus oral buprenorphine as opioid maintenance treatment during pregnancy-maternal and neonatal outcomes.

41. Analysis of rising cases of adolescent opioid use presentations to the emergency department and their management.

42. Precipitated opioid withdrawal in a patient started on olanzapine/samidorphan.

43. Depot buprenorphine injections for opioid use disorder: Patient information needs and preferences

44. AATOD white paper details how OTPs and buprenorphine providers can collaborate

46. Buprenorphine dispensing before and after the April 2021 X-Waiver exemptions: An interrupted time series analysis.

47. Maternal opioid use disorder and infant mortality in Wisconsin, United States, 2010-2018.

48. Sex specific effects of buprenorphine on adult hippocampal neurogenesis and behavioral outcomes during the acute phase after pediatric traumatic brain injury in mice.

49. Factors associated with frequent buprenorphine / naloxone initiation in a national survey of Canadian emergency physicians.

50. Association between high-threshold practices and buprenorphine treatment termination.